Article
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
JCO precision oncology - 1 Nov 2024
Priantti Jonathan N, Fujiwara Yu, Aquino de Moraes Francisco Cezar, Michelon Isabella, Castro Caio, Leighl Natasha B, Cavalcante Ludimila, Addeo Alfredo, Bar Jair, Horita Nobuyuki, Cortellini Alessio, Nassar Amin H, Vilbert Maysa, Naqash Abdul Rafeh
Abstract excerpt
PURPOSE: The activity of osimertinib is not fully characterized in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations. Therefore, we conducted a systematic review and meta-analysis to assess the safety and efficacy of osimertinib in patients with NSCLC harboring uncommon somatic EGFR mutations. METHODS: PubMed, Embase, and the Cochrane Library were searched for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.